Tezspire approved for self-administration in the US with a new pre-filled pen
First and only respiratory biologic without phenotype or biomarker limitations that offers the choice of administration at home or in a doctor’s office.AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. Tezspire is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.[1] The approval by the US Food and Drug Administration (FDA) was based on results from the